EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

NCT05998863 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Osteoporosis
Hypomagnesemia

Interventions

DRUG: EffCaMgCit
OTHER: Placebo

Sponsor

University of Texas Southwestern Medical Center